Compare DMLP & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMLP | XERS |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2002 | 2021 |
| Metric | DMLP | XERS |
|---|---|---|
| Price | $28.11 | $8.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 268.3K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.98% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $152,832,000.00 | $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | $23.09 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $20.85 | $5.25 |
| 52 Week High | $28.95 | $10.08 |
| Indicator | DMLP | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 62.91 | 55.51 |
| Support Level | $26.43 | $6.98 |
| Resistance Level | $28.72 | $9.01 |
| Average True Range (ATR) | 0.55 | 0.34 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 93.51 | 85.76 |
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonuses, and others.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.